1. A novel NF2 splicing mutant causes neurofibromatosis type 2 via liquid-liquid phase separation with large tumor suppressor and Hippo pathway
- Author
-
Jia, Zexiao, Yang, Shuxu, Li, Mengyao, Lei, Zhaoying, Ding, Xue, Fan, Mingjie, Wang, Dixian, Xie, Dajiang, Zhou, Hui, Qiu, Yue, Zhuang, Qianqian, Li, Dan, Yang, Wei, Qi, Xuchen, Cang, Xiaohui, Zhao, Jing-Wei, Wang, Wenqi, Lin, Aifu, and Yan, Qingfeng
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Neurofibromatosis ,Cancer ,Pediatric ,Neurosciences ,Genetics ,Rare Diseases ,Aetiology ,2.1 Biological and endogenous factors ,Clinical genetics ,Functional aspects of cell biology ,Pathophysiology - Abstract
Neurofibromatosis type 2 is an autosomal dominant multiple neoplasia syndrome and is usually caused by mutations in the neurofibromin 2 (NF2) gene, which encodes a tumor suppressor and initiates the Hippo pathway. However, the mechanism by which NF2 functions in the Hippo pathway isn't fully understood. Here we identified a NF2 c.770-784del mutation from a neurofibromatosis type 2 family. MD simulations showed that this mutation significantly changed the structure of the F3 module of the NF2-FERM domain. Functional assays indicated that the NF2 c.770-784del variant formed LLPS in the cytoplasm with LATS to restrain LATS plasma membrane localization and inactivated the Hippo pathway. Besides, this deletion partly caused a skipping of exon 8 and reduced the protein level of NF2, collectively promoting proliferation and tumorigenesis of meningeal cells. We identified an unrecognized mechanism of LLPS and splicing skipping for the NF2-induced Hippo pathway, which provided new insight into the pathogenesis of neurofibromatosis type 2.
- Published
- 2022